Latin America Recombinant Protein Therapeutics Cdmo Market Size & Outlook
Latin America recombinant protein therapeutics cdmo market, 2018-2030 (US$M)
Related Markets
Latin America recombinant protein therapeutics cdmo market highlights
- The Latin America recombinant protein therapeutics cdmo market generated a revenue of USD 769.3 million in 2023.
- The market is expected to grow at a CAGR of 13.1% from 2024 to 2030.
- In terms of segment, interferons was the largest revenue generating type in 2023.
- Growth Hormones is the most lucrative type segment registering the fastest growth during the forecast period.
- Country-wise, Brazil is expected to register the highest CAGR from 2024 to 2030.
Latin America data book summary
| Market revenue in 2023 | USD 769.3 million |
| Market revenue in 2030 | USD 1,818.4 million |
| Growth rate | 13.1% (CAGR from 2023 to 2030) |
| Largest segment | Interferons |
| Fastest growing segment | Growth Hormones |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Growth Hormones, Interferons, Vaccines, Immunostimulating Agents |
| Key market players worldwide | Lonza Group Ltd, Catalent Inc, FUJIFILM Holdings Corp, WuXi Biologics (Cayman) Inc, Batavia Biosciences, Richter-Helm, Curia, HALIX, Biovian, Enzene Biosciences |
Other key industry trends
- In terms of revenue, Latin America region accounted for 3.7% of the global recombinant protein therapeutics cdmo market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 13,871.8 million by 2030.
Interferons was the largest segment with a revenue share of 21.47% in 2023. Horizon Databook has segmented the Latin America recombinant protein therapeutics cdmo market based on growth hormones, interferons, vaccines, immunostimulating agents covering the revenue growth of each sub-segment from 2018 to 2030.
Latin American region captured 3.7% of the global recombinant protein therapeutics CDMO market in 2023 and is anticipated to exhibit significant growth opportunities in the coming years. The increasing number of clinical trials is expected to drive the recombinant protein therapeutics CDMO market in Latin America as biotechnology & pharmaceutical companies invest in biologic product development.
In addition, the growing number of clinical trials conducted by CROs focusing on the diversified population is expected to propel market growth. Moreover, the study of this diverse population is expected to yield high-quality results for drug developers. Hence, the increasing number of pharmaceutical companies in the region and the rising efforts of healthcare organizations to prevent infectious diseases are expected to impel market growth.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Recombinant Protein Therapeutics CDMO Market Scope
Recombinant Protein Therapeutics CDMO Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Latin America recombinant protein therapeutics cdmo market size, by country, 2018-2030 (US$M)
Latin America Recombinant Protein Therapeutics CDMO Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
